Proportion of drug-related serious rare blood dyscrasias: Estimates from the Berlin Case-Control Surveillance Study

American Journal of Hematology

Volumn 77, Issue 3, 2004, Pages 316-318

  Andersohn, Frank ^a   Bronder, Elisabeth ^a   Klimpel, Andreas ^a   Garbe, Edeltraut ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Acute agranulocytosis; Aplastic anemia; Blood dyscrasias; Immune hemolytic anemia; Immune thrombocytopenia; Thrombotic thrombocytopenic purpura hemolytic uremic syndrome

Indexed keywords

ABCIXIMAB; ALLOPURINOL; ALPHA INTERFERON; AMLODIPINE; ATOVAQUONE; CARBAMAZEPINE; CEFTRIAXONE; CLOZAPINE; COBALAMIN; COTRIMOXAZOLE; DICLOFENAC; DIPYRONE; FLUDARABINE; GENTAMICIN; LISINOPRIL; LORATADINE; METHOTREXATE; MINOCYCLINE; MIRTAZAPINE; PENICILLIN G; PENTOXIFYLLINE; PERAZINE; PHENOBARBITAL; PHENYTOIN; PROPYLTHIOURACIL; ROFECOXIB; ROXITHROMYCIN; SALAZOSULFAPYRIDINE; THIAMAZOLE; UNINDEXED DRUG;

APLASTIC ANEMIA; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; BLOOD DYSCRASIA; BLOOD TOXICITY; CASE CONTROL STUDY; CONTROLLED STUDY; DATA ANALYSIS; DISEASE SEVERITY; FEMALE; GERMANY; GRANULOCYTOSIS; HEALTH SURVEY; HEMOLYTIC UREMIC SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOCYTOPENIA; THROMBOCYTOPENIC PURPURA;

ADVERSE DRUG REACTION REPORTING SYSTEMS; BERLIN; CASE-CONTROL STUDIES; HEMATOLOGIC DISEASES; HUMANS; POPULATION SURVEILLANCE;

EID: 7244239052     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.20176     Document Type: Article

References (8)

1. Kaufman DW, Kelly JP, Jurgelon JM, et al. Drugs in the aetiology of agranulocytosis and aplastic anaemia. Eur J Haematol Suppl 1996;60:23-30.
2. Heimpel H. When should the clinician suspect a drug-induced blood dyscrasia, and how should he proceed? Eur J Haematol Suppl 1996;60:11-15.
3. Heimpel H. Epidemiology and etiology of aplastic anemia. In: Schrezenmeier H. Bacigalupo A, editors. Aplastic anemia. Cambridge, England: Cambridge University Press; 2000. p 97-116.
4. World Health Organisation. WHO causality assessment method (http://www.who-umc.org/defs.html).
5. Mir MA, Geary CG. Aplastic anaemia: an analysis of 174 patients. Postgrad Med J 1980;56:322-329.
6. George JN, Vesely SK, Terrell DR. The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry: a community perspective of patients with clinically diagnosed TTP-HUS. Semin Hematol 2004;41:60-67.
7. Marin P. Clinical presentation, natural course, and prognostic factors. In: Schrezenmeier H, Bacigalupo A, editors. Aplastic anemia. Cambridge, England: Cambridge University Press; 2000. p 117-136.
8. Salama A, Kroll H, Wittmann G, Mueller-Eckhardt C. Diclofenac-induced immune haemolytic anaemia: simultaneous occurrence of red blood cell autoantibodies and drug-dependent antibodies. Br J Haematol 1996;95:640-644.